TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

More documents

Recommendations

Info

5A.149 Hartzell JD et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009;48:1724-8. 5A.150 Falagas ME et al. Nephrotoxicity of colistin: new insight into an old antibiotic. Clin Infect Dis 2009; 48:1729-31. 5A.151 Wahby K et al. Intravenous and inhalational colistin-induced respiratory failure. Clin Infect Dis 2010; 50:e38-40. 5A.152 Velissariou IM. Use of linezolid in children: an overview of recent advances. Expert Rev Anti Infect Ther 2006;4:947-52. 5A.153 Herrmann DJ et al. Linezolid for the treatment of drug-resistant infections. Expert Rev Anti Infect Ther 2008;6:825-48. 5A.154 Falagas ME et al. Linezolid versus glycopeptide or β-lactam for the treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 2008;8:53-66. 5A.155 De Vriese AS et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 2006;42:1111-7. 5A.156 McKee EE et al. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob Agents Chemother 2006;50:2042-9. 5A.157 Stevens DL et al. A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti Infect Ther 2004;2:51-9. 5A.158 Bassetti M et al. Role of linezolid in the treatment of orthopedic infections. Expert Rev Anti Infect Ther 2005;3:343-52. 5A.159 Razonable RR et al. Linezolid therapy for orthopedic infections. Mayo Clin Proc 2004;79:1137-44. 5A.160 Wu VC et al. High frequency of linezolid-associated thrombocytopenia and anemia along patients with end-stage renal disease. Clin Infect Dis 2006;42:66-72. 5A.161 Attassi K et al. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 2002;34:695-8. 5A.162 de Antonio JM et al. Thrombocytopenia and anemia associated with linezolid in patients with kidney failure. Clin Infect Dis 2006;42:1500. 5A.163 Apodaca AA et al. Linezolid induced lactic acidosis. N Engl J Med 2003;348:86-7. 5A.164 Bressler AM et al. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 2004;4:528-31. 5A.165 Linam WL et al. Peripheral neuropathy in an adolescent treated with linezolid. Pediatr Infect Dis J 2009;28:149-51. 5A.166 Frippiat F et al. Severe bilateral optic neuritis associated with prolonged linezolid therapy. J Antimicrob Chemother 2004;53:1114-5. 5A.167 Saijo T et al. Linezolid induced optic neuropathy. Am J Ophthalmol 2005;139:1114-6. 5A.168 Lawrence KR et al. Serotonin toxicity associated with the use of linezolid: a review of post-marketing data. Clin Infect Dis 2006;42:1578-83. 5A.169 Taylor JJ et al. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis 2006;43:180-7. 5A.170 Wigen CL et al. Serotonin syndrome and linezolid. Clin Infect Dis 2002;34:1651-2. 5A.171 Bernard L et al. Serotonin syndrome after concomitant treatment with linezolid and citalopram. Clin Infect Dis 2003;36:1197. 5A.172 Hammer MC et al. Linezolid-induced acute interstitial nephritis. Infect Dis Clin Pract 2009;17:61-2. 5A.173 Velema MS et al. DRESS syndrome caused by nitrofurantoin. Neth J Med 2009;67:147-9. 5A.174 Forrest GN et al. Rifampin combination therapy for nonmycobacterial infections. Clin Microbiol Rev 2010;23:14-34. 5A.175 Kaye D. Current use for old antibacterial agents: polymyxins, rifampin, and aminoglycosides. Infect Dis Clin North Am 2004;18:669-89. 5A.176 Strevel EL et al. Severe and protracted hypoglycaemia associated with co-trimoxazole use. Lancet Infect Dis 2006;6:178-82. 5A.177 Masters PA et al. Trimethoprim-sulfamethoxazole revisited. Arch Intern Med 2003;163:402-10. 5A.178 Strevel EL et al. Severe and protracted hypoglycaemia associated with co-trimoxazole use. Lancet Infect Dis 2006;6:178-82. 5A.179 Trepanier LA et al. Plasma ascorbate deficiency is associated with impaired reduction of sulfamethoxazole nitroso in HIV infection. J Acquir Immune Defic Syndr 2004;36:1041-50. 5B.1 Ball P. Quinolone generations: natural history or natural selection? J Antimicrob Chemother 2000; 46(topic T1):17-24. 5B.2 Van Bambeke F et al. Quinolones in 2005: an update. Clin Microbiol Infect 2005;11:256-80. 5C.1 American Academy of Pediatrics Committee in Fetus and Newborn. Age terminology during the perinatal period. Pediatrics 2004;114:1362-4. 5C.2 Henry NK et al. Antimicrobial therapy for infants and children: guidelines for the inpatient and outpatient practice of pediatric infectious diseases. Mayo Clin Proc 2000;75:86-97. 5C.3 American Academy of Pediatrics Committee on Infectious Diseases. Antibacterial drugs for pediatric patients beyond the newborn period. Red Book 2009;28:747-57. 5C.4 Bowlware Kl et al. Antibacterial agents in pediatrics. Infect Dis Clin North Am 2004;18:513-31. 5C.5 Velissariou IM. The use of fluoroquinolones in children: recent advances. Expert Rev Anti Infect Ther 2006;4:853-60. 5C.6 Schaad UB. Fluoroquinolone antibiotics in infants and children. Infect Dis Clin North Am 2005;19: 617-28. 5C.7 Schaad UB. Will fluoroquinolones ever be recommended for common infections in children? Pediatr Infect Dis J 2007;26:865-7. 5C.8 Gendrel D et al. Fluoroquinolones in paediatrics: a risk for the patient or for the community? Lancet Infect Dis 2003;3:537-46. 5C.9 Tamma P et al. Use of colistin in children. Pediatr Infect Dis J 2009;28:534-5. 5C.10 Dehority W. Use of vancomycin in pediatrics. Pediatr Infect Dis J 2010;29:462-4. 5C.11 Frymoyer A et al. Current recommended dosing of vancomycin for children with invasive methicillinresistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J 2009;28:398-402. 5C.12 Velissariou IM. Use of linezolid in children: an overview of recent advances. Expert Rev Anti Infect
Ther 2006;4:947-52. 5D.1 Demirovic JA et al. Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm 2009;66:642-8. 5D.2 Pai MP et al. Antimicrobial dosing considerations in obese adult patients: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2007;29:1081-91. 5D.3 Erstad BL. Dosing of medications in morbidly obese patients in the intensive care setting. Intensive Care Med 2004:30:18-32. 5D.4 Wurtz R et al. Antimicrobial dosing in obese patients. Clin Infect Dis 1997;25:112-8. 5D.5 Falagas M et al. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet 2010;375:248-51. 5D.6 Mushatt DM et al. Antibiotic dosing in slow extended daily dialysis. Clin Infect Dis 2009;49:433-7. 5D.7 Livornese LL et al. Use of antibacterial agents in renal failure. Infect Dis Clin North Am 2004;18: 551-79. 5D.8 Trotman RL et al. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005;41:1159-66. 5D.9 Levey AS et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-70. 5D.10 Lee NL et al. β-lactam antibiotic and β-lactamase inhibitor combinations. J Am Med Assoc 2001; 285:386-8. 5E.1 Rybak MJ. Pharmacodynamics: relation to antimicrobial resistance. Am J Med 2006;119(6 suppl.): S37-44. 5E.2 Scaglione F et al. Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection. Expert Rev Anti Infect Ther 2006;4:479-90. 5E.3 Schuck EL et al. Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents. Expert Rev Anti Infect Ther 2005;3:361-73. 5E.4 Drusano GL. Antimicrobial pharmacodynamics: critical interactions of ―bug and drug‖. Nat Rev Microbiol 2004;2:289-300. 5E.5 Levison ME. Pharmacodynamics of antimicrobial drugs. Infect Dis Clin North Am 2004;18:451-65. 5E.6 Ambrose PG et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it‘s not just for mice anymore. Clin Infect Dis 2007;44:79-86. 5E.7 Drusano GL. Pharmacokinetics and pharmacodynamics of antimicrobials. Clin Infect Dis 2007;45 (suppl. 1):S89-95. 5E.8 Trexler Hessen M et al. Principles of use of antibacterial agents. Infect Dis Clin North Am 2004;18: 435-50. 5E.9 Bergman SJ et al. Pharmacokinetic and pharmacodynamic aspects of antibiotic use in high-risk populations. Infect Dis Clin North Am 2007;21:821-46. 5E.10 Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides and linezolid. Infect Dis Clin North Am 2003;17:479-501. 5E.11 Ambrose PG et al. Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am 2003;17: 529-43. 5E.12 Maglio D et al. Impact of pharmacodynamics on dosing of macrolides, azalides, and ketolides. Infect Dis Clin North Am 2003;17:563-77. 5F.1 Rea RS et al. Optimizing use of aminoglycosides in the critically ill. Semin Respir Crit Care Med 2007;28:596-603. 5F.2 Begg EJ et al. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol 2001;52 (suppl. 1):35S-43S. 5F.3 Kitzis MD et al. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections. Clin Microbiol Infect 2006;12:92-5. 5F.4 Rybak M et al. Therapeutic monitoring of vancomycin in adult patients:a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66:82-98. 5F.5 Rybak M et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health System Pharmacists and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009;49:325-7. 5F.6 Begg EJ et al. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol 2001;52 (suppl. 1):35S-43S. 5F.7 MacGowan AP. Pharmacodynamics, pharmacokinetics and therapeutic drug monitoring of glycopeptides.Ther Drug Monit 1998;20:473-7. 5F.8 MacGowan AP. Pharmacodynamics, pharmacokinetics and therapeutic drug monitoring of glycopeptides.Ther Drug Monit 1998;20:473-7. 5F.9 Soy D et al. Teicoplanin population pharmacokinetic analysis in hospitalized patients. Ther Drug Monit 2006;28:737-43. 5F.10 Wilson A et al. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet 2000;39:167-83. 5F.11 Begg EJ et al. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol 2001;52 (suppl. 1):35S-43S. 5F.12 Pea F et al. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. J Antimicrob Chemother 2003;51:971-5. 5F.13 Lamont E et al. Development of teicoplanin dosing guidelines for patients treated with an outpatient parenteral therapy (OPAT) programme. J Antimicrob Chemother 2009;64:181-7. 6A.1 Lipsky BA et al. Topical antimicrobial therapy for treating chronic wounds. Clin Infect Dis 2009;49: 1541-9. 6A.2 Lio PA et al. Topical antibacterial agents. Infect Dis Clin North Am 2009;23:945-63. 6A.3 Elston DM. Topical antibiotics in dermatology: emerging patterns of resistance. Dermatol Clin 2009; 27:25-31. 6A.4 Pangilinan R et al. Topical antibiotic treatment for uncomplicated skin and skin structure infections: review of the literature. Expert Rev Anti Infect Ther 2009;7:957-65. 6A.5 Greenhalgh DG et al. Topical antimicrobial agents for burn wounds. Clin Plast Surg 2009;36:597- 606.
Page 1 and 2: TABLE 39A LIST OF PUBLICATIONS REFE
Page 3 and 4: 1.89 Laupland KB. Vascular and para
Page 5 and 6: of NICE guidance. Br Med J 2008;337
Page 7 and 8: tions à Clostridium difficile dans
Page 9 and 10: sis of placebo-controlled trials. C
Page 11 and 12: 1.446 Centers for Disease Control a
Page 13 and 14: 1.532 Olaison L et al. Enterococcal
Page 15 and 16: 1.615 Muder RR et al. Isolation of
Page 17 and 18: 2005;352:865-74. 1.699 Brown-Elliot
Page 19 and 20: 2009;123:1108-15. 1.782 Ellis MW. A
Page 21 and 22: 1.873 Korting HC et al. Current top
Page 23 and 24: 1.970 Thomas RJ et al. Current mana
Page 25 and 26: of severe respiratory failure. Clin
Page 27 and 28: 1.1166 Aldape MJ et al. Clostridium
Page 29 and 30: 2A.36 Wormser GP. Early Lyme diseas
Page 31 and 32: test methodology. Eur J Clin Microb
Page 33 and 34: 2B.39 Cookson BD et al. Guidelines
Page 35 and 36: 2009;15(suppl. 3):7-11. 2B.115 Jaco
Page 37 and 38: 82. 4A.87 de Smet AM et al. Deconta
Page 39 and 40: after acute pyelonephritis: a multi
Page 41 and 42: for intensive care patients with no
Page 43: among hospitalized patients. Clin I
Page 47 and 48: 7.38 Meersseman W et al. Invasive a
Page 49 and 50: 7.121 Walsh TJ et al. All catheter
Page 51 and 52: nail onychomycosis. J Eur Acad Derm
Page 53 and 54: 2006. Clin Infect Dis 2006;43:1580-
Page 55 and 56: 9A.5 Andes D. Pharmacokinetics and
Page 57 and 58: factor and other newly approved bio
Page 59 and 60: cument E.DEF 8.1). Report of the Su
Page 61 and 62: Br J Dermatol 2004;151:1096-100. 11
Page 63 and 64: new prediction equation. Ann Intern
Page 65 and 66: 14A.93 Sundar S et al. New treatmen
Page 67 and 68: eview. Obstet Gynecol 2005;105:857-
Page 69 and 70: 2003;1:471-82. 14A.278 Walker MD et
Page 71 and 72: 14B.4 Checkley AM et al. Eosinophil
Page 73 and 74: 18.12 Panel on Antiretroviral Thera
Page 75 and 76: 18.91 Lesho E. Evidence base for us
Page 77 and 78: tients. J Antimicrob Chemother 2009
Page 79 and 80: duct characteristics. Available at:
Page 81 and 82: _Product_Information/human/000338/W
Page 83 and 84: 114:23-33. 21.80 Jabs DA et al. Fom
Page 85 and 86: North Am 2006;20:155-74. 21.176 Nas
Page 87 and 88: 1995;14:827-32. 21.264 Scott LL. Pe
Page 89 and 90: 21.358 Calabrese LH et al. Viral Ar
Page 91 and 92: 24. 21.452 Jeha LE et al. Long term
Page 93 and 94: induced functional androgen deficie
Page 95 and 96:
25A.27 Conseil Supérieur de la San
Page 97 and 98:
product characteristics. Available
Page 99 and 100:
mortality after kidney transplantat
Page 101 and 102:
33A.1 Kearney BP et al. The penetra
Page 103 and 104:
Clin Plast Surg Clinics in Plastic
Page 105 and 106:
Mycopathologia Mycopathologia Mycos
show all

TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?